A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505
SOSIP.664 gp140 Vaccine, Adjuvanted, given to a Population of Adults in Good General Health
Who have Received 3 doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
Phase:
Phase 1
Details
Lead Sponsor:
International AIDS Vaccine Initiative
Collaborators:
Access to Advanced Health Institute (AAHI) National Institute of Allergy and Infectious Diseases (NIAID)